Antimanic-like effects of (R)-(-)-carvone and (S)-(+)-carvone in mice

Neuroscience Letters

Volumn 619, Issue , 2016, Pages 43-48

  Nogoceke, Francianne P ^a   Barcaro, Inara M R ^a   de Sousa, Damião P ^b   Andreatini, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Essential oil; Mania; Natural product; Psychostimulant; Sleep deprivation

Indexed keywords

CARVONE; LITHIUM CARBONATE; METHYLPHENIDATE; TERPENE; TRANQUILIZER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMANIC LIKE EFFECT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENANTIOMER; EXPERIMENTAL HYPERACTIVITY; LOCOMOTION; LONG TERM CARE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEDATION; SLEEP DEPRIVATION; ANIMAL; BIPOLAR DISORDER; CHEMISTRY; DRUG EFFECTS; MOTOR ACTIVITY; PSYCHOLOGY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; MALE; METHYLPHENIDATE; MICE; MONOTERPENES; MOTOR ACTIVITY; SLEEP DEPRIVATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84961170651     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.03.013     Document Type: Article

References (48)

1. Goodwin F.K., Jamison K.R., Ghaemi S.N. Manic-depressive Illness: Bipolar Disorders and Recurrent Depression 2007, Oxford University Press, New York. 2nd ed.
2. Young J.W., Henry B.L., Geyer M.A. Predictive animal models of mania: hits, misses and future directions. Br. J. Pharmacol. 2011, 164:1263-1284.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Publishing, Washington DC. 5th ed.
4. Yildiz A., Vieta E., Tohen M., Baldessarini R.J. Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int. J. Neuropsychopharmacol. 2011, 14:863-875.
5. Machado-Vieira R., Kapczinski F., Soares J.C. Perspectives for the development of animal models of bipolar disorder: prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:209-224.
6. Nierenberg A.A. A critical appraisal of treatments for bipolar disorder. Prim. Care Companion J. Clin. Psychiatry 2010, 12:23-29.
7. de Almeida R.N., Motta S.C., Leite J.R. Óleos essenciais com propriedades anticonvulsivantes. Bol. Latinoam. Caribe Plantas Med. Aromat. 2003, 2:3-6.
8. de Sousa D.P., de Farias Nóbrega F., de Almeida R.N. Influence of the chirality of (R)-(-)-and (S)-(+)-carvone in the central nervous system: a comparative study. Chirality 2007, 19:264-268.
9. Gonçalves J.C.R., Oliveira F.S., Benedito R.B., de Sousa D.P., de Almeida R.N., de Araújo D.A.M. Antinociceptive activity of (-)-carvone: evidence of association with decreased peripheral nerve excitability. Biol. Pharm. Bull. 2008, 31:1017-1020.
10. Woelk H., Schläfke S. A multi-center double-blind, randomised study of the Lavender oil preparation silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine 2010, 17:94-99.
11. Gonçalves J.C.R., Alves A.M.H., de Araújo A.E.V., Cruz J.S., Araújo D.A.M. Distinct effects of carvone analogues on the isolated nerve of rats. Eur. J. Pharmacol. 2010, 645:108-112.
12. Lambert J., Compton R.N., Crawford T.D. The optical activity of carvone: a theoretical and experimental investigation. J. Chem. Phys. 2012, 136:114512.
13. Souza F.V., da Rocha M.B., de Souza D.P., Marçal R.M. (-)-Carvone: antispasmodic effect and mode of action. Fitoterapia 2013, 85:20-24.
14. Hatano V.Y., Torricelli A.S., Giassi A.C., Coslope L.A., Viana M.B. Anxiolytic effects of repeated treatment with an essential oil from Lippia alba and (R)-(-)-carvone in the elevated T-maze. Braz. J. Med. Biol. Res. 2012, 45:238-243.
15. Buchbauer G., Jäger W., Gruber A., Dietrich H. R-(+)- and S-(-)-carvone: influence of chirality on locomotion activity in mice. Flavour Fragr. J. 2005, 20:686-689.
16. Costa D.A., de Oliveira G.A., Lima T.C., dos Santos P.S., de Sousa D.P., de Freitas R.M. Anticonvulsant and antioxidant effects of cyano-carvone and its action on acetylcholinesterase activity in mice hippocampus. Cell. Mol. Neurobiol. 2012, 32:633-640.
17. Costa D.A., Oliveira G.A., Costa J.P., Souza G.F., De Sousa D.P., Freitas R.M. Avaliação da toxicidade aguda e efeito ansiolítico de um derivado sintético da carvona. Rev. Bras. Ciênc. Saúde 2012, 16:303-310.
18. Marques T.H.C., Marques M.L., Medeiros J.V., Lima R.O. A.L. dos Reis Barbosa, T.C., LIma, D.P. de Sousa, R.M. de Freitas, Cyane-carvone, a synthetic derivative of carvone, inhibits inflammatory response by reducing cytokine production and oxidative stress and shows antinociceptive effect in mice. Inflammation 2014, 37:966-977.
19. Marques T.H.C., Marques M.L., Medeiros J.V., Lima T.C., de Sousa D.P., de Freitas R.M. Anticonvulsant effects of acute treatment with cyane-carvone at repeated oral doses in epilepsy models. Pharmacol. Biochem. Behav. 2014, 124:421-424.
20. de Sousa D.P., Nobrega F.F., Claudino F.S., de Almeida R.N., Leite J.R., Mattei R. Pharmacological effects of the monoterpene α, β-epoxy-carvone in mice. Braz. J. Pharmacogn. 2007, 17:170-175.
21. da Rocha M.L., Oliveira L.E., Patricio Santos C.C., de Souza D.P., de Almeida R.N., Araújo D.A. Antinociceptive and anti-inflammatory effects of the monoterpene α,β-epoxy-carvone in mice. J. Nat. Med. 2013, 67:743-749.
22. de Almeida R.N., de Souza D.P., Nobrega F.F.F., Claudino F.S., Araújo D.A.M., Leite J.R., Mattei R. Anticonvulsant effect of a natural compound α,β-epoxy-carvone and its action on the nerve excitability. Neurosci. Lett. 2008, 443:51-55.
23. de Sousa D.P., de Sousa Oliveira F., de Almeida R.N. Evaluation of the central activity of hydroxydihydrocarvone. Biol. Pharm. Bull. 2006, 29:811-812.
24. Sabioni P., Baretta I.P., Ninomiya E.M., Gustafson L., Rodrigues A.L., Andreatini R. The antimanic-like effect of tamoxifen: behavioural comparison with other PKC-inhibiting and antiestrogenic drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1927-1931.
25. Pereira M., Martynhak B.J., Baretta I.P., Correia D., Siba I.P., Andreatini R. Antimanic-like effect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene. Neurosci. Lett. 2011, 500:95-98.
26. Armani F., Andersen M.L., Andreatini R., Frussa-Filho R., Tufik S., Galduróz J.C. Successful combined therapy with tamoxifen and lithium in a paradoxical sleep deprivation-induced mania model. CNS Neurosci. Ther. 2012, 18:119-125.
27. Gessa G.L., Pani L., Fadda P., Fratta W. Sleep deprivation in the rat: an animal model of mania. Eur. Neuropsychopharmacol. 1995, 5:89-93.
28. Einat H. Modelling facets of mania: new directions related to the notion of endophenotypes. J. Psychopharmacol. 2006, 20:714-722.
29. Streck E.L., Scaini G., Jeremias G.C., Rezin G.T., Gonçalves C.L., Ferreira G.K., Réus G.Z., Resende W.R., Valvassori S.S., Kapczinski F., Andersen M.L., Quevedo J. Effects of mood stabilizers on brain energy metabolism in mice submitted to an animal model of mania induced by paradoxical sleep deprivation. Neurochem. Res. 2015, 40:1144-1152.
30. Abrial E., Bétourné A., Etiévant A., Lucas G., Scarna H., Lambás-Señas L., Haddjeri N. Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania. Int. J. Neuropsychopharmacol. 2015, 18:1-11.
31. Abrial E., Etievant A., Bétry C., Scarna H., Lucas G., Haddjeri N., Lambás-Señas L. Protein kinase C regulates mood-related behaviors and adult hippocampal cell proliferation in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 43:40-48.
32. Gould T.J., Keith R.A., Bhat R.V. Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav. Brain Res. 2001, 118:95-105.
33. Barbosa F.J., Hesse B., de Almeida R.B., Baretta I.P., Boerngen-Lacerda R., Andreatini R. Magnesium sulfate and sodium valproate block methylphenidate-induced hyperlocomotion, an animal model of mania. Pharmacol. Rep. 2011, 63:64-70.
34. Tonelli D.A., Pereira M., Siba I.P., Martynhak B.J., Correia D., Casarotto P.C., Biojone C., Guimarães F.S., Joca S.L., Andreatini R. The antimanic-like effect of phenytoin and carbamazepine on methylphenidate-induced hyperlocomotion: role of voltage-gated sodium channels. Fundam. Clin. Pharmacol. 2013, 27:650-655.
35. Arunagiri P., Rajeshwaran K., Shanthakumar J., Tamilselvan T., Balamurugan E. Combination of omega-3 fatty acids lithium, and aripiprazole reduces oxidative stress in brain of mice with mania. Biol. Trace Elem. Res. 2014, 160:409-417.
36. Kara N.Z., Karpel O., Toker L., Agam G., Belmaker R.H., Einat H. Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice. Acta Neuropsychiatr. 2014, 26:29-34.
37. Ene H.M., Kara N.Z., Einat H. The effects of the atypical antipsychotic asenapine in a strain-specific battery of tests for mania-like behaviors. Behav. Pharmacol. 2015, 26:331-337.
38. Zhou Z., Wang Y., Tan H., Bharti V., Che Y., Wang J.F. Chronic treatment with mood stabilizer lithium inhibits amphetamine-induced risk-taking manic-like behaviors. Neurosci. Lett. 2015, 603:84-88.
39. Colombo C., Benedetti F., Barbini B., Campori E., Smeraldi E. Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Res. 1999, 86:267-270.
40. A and glycine receptor currents by menthol and related monoterpenoids. Eur. J. Pharmacol. 2004, 506:9-16.
41. Gould T.D., Quiroz J.A., Singh J., Zarate C.A., Manji H.K. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol. Psychiatry 2004, 9:734-755.
42. Bourin M., Chenu F., Hascoet M. The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers. Curr. Drug Targets 2009, 10:1052-1060.
43. Petty F., Sherman A.D. Plasma GABA levels in psychiatric illness. J. Affect. Disord. 1984, 6:131-138.
44. Brady R.O., McCarthy J.M., Prescot A.P., Jensen J.E., Cooper A.J., Cohen B.M., Renshaw P.F., Ongür D. Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. Bipolar Disord. 2013, 15:434-439.
45. Chouinard G. Clonazepam in acute and maintenance treatment of bipolar affective disorder. J. Clin. Psychiatry 1987, 29-37. 48 Suppl.
46. Edwards R., Stephenson U., Flewett T. Clonazepam in acute mania: a double blind trial. Aust. N. Z. J. Psychiatry 1991, 25:238-242.
47. Chouinard G., Annable L., Turnier L., Holobow N., Szkrumelak N. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can. J. Psychiatry 1993, 38(Suppl. 4):114-121.
48. A receptor in primary cultures of rat cortical neurons. Chirality 2014, 26:368-372.